Core Viewpoint - iSpecimen Inc. has entered into a securities purchase agreement with accredited investors, aiming to raise approximately $5.5 million through the issuance of Series C Convertible Preferred Stock [1][2][3] Group 1: Offering Details - The company will issue 6,875 shares of Series C Convertible Preferred Stock at a price of $800 per share, convertible into common stock at a conversion price of 85% of the closing price prior to each conversion date [2][3] - The offering is expected to close on or about December 31, 2025, pending customary closing conditions [3] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for marketing, working capital, and general corporate purposes [3] Group 3: Regulatory Information - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Act or applicable state laws, limiting their sale to accredited investors [4]